research Tolerance and efficacy of a new emollient barrier cream in pediatric and adult population with mild to moderate atopic dermatitis
The new cream is safe and effective for mild to moderate atopic dermatitis.
Search
for
Sort by
Research
240-270 / 1000+ results
research USE OF RITLECITINIB FOR THE TREATMENT OF ALOPECIA AREATA
Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
research Hyperammonemia with Valproic Acid: Colonic Ischemia Associated with “Triptan” Use Visual Side Effects with Pegylated Interferon: Alopecia Areata with Infliximab: Adverse Effects Seen with Medications Used for Irritable Bowel Syndrome
Certain medications can cause serious side effects, so it's important to report them.
research Read-Through for Nonsense Mutations in Type XVII Collagen‒Deficient Junctional Epidermolysis Bullosa
A new therapy for a skin blistering condition has not been developed yet.
research Biologics in the management of childhood atopic dermatitis
Biologics, especially Dupilumab, are effective and safe for treating severe childhood eczema.
research Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience
Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.
research Proteasome Inhibitors: An Expanding Army Attacking a Unique Target
Proteasome inhibitors are promising treatments for various cancers, autoimmune diseases, and other conditions.
research The Efficacy of Baricitinib as a Treatment Option for Alopecia, In Terms of Promoting Hair Regrowth and Improving Patient Reported Outcomes
Baricitinib effectively promotes hair regrowth in severe alopecia with minimal side effects.
research 1113 Targeting anti-inflammatory immunonanocarriers to human and murine neutrophils via Ly6 antigen for psoriasiform dermatitis alleviation
The study created special nanoparticles that effectively deliver an anti-inflammatory drug to treat skin inflammation in psoriasis.
research BI02 (P97): Epidermal growth factor receptor inhibitor therapy induces a distinct inflammatory hair follicle response that includes a collapse of immune privilege
research Ixekizumab Improved Refractory Erythrodermic Psoriasis with Comorbid Diffuse Alopecia: A Case Report with 52-Week Follow-Up
Ixekizumab effectively treated severe psoriasis and hair loss in a patient.
research Immune-Mediated Skin Reactions Induced by Recombinant Antibodies and Other TNF-Alpha Inhibitors
TNF-alpha inhibitors can cause various immune-related skin issues.
research Learning From Success and Failure: Biologics for Non-approved Skin Diseases
Biologics show promise in treating various stubborn skin diseases, but more research and better reimbursement criteria are needed.
research Cemiplimab-Induced Alopecia Areata
A man developed temporary hair loss after taking a cancer drug, which might indicate a better treatment response.
research Cyclosporine Therapy for Bullous Erythema Multiforme
Cyclosporine cleared a woman's resistant skin condition quickly and kept it away for over a year.
research 709 Nitric oxide-releasing topical therapeutic agent for atopic dermatitis
SB414 may be an effective treatment for atopic dermatitis by reducing swelling and bacterial infection.
research 08.33 Treatment of rheumatoid arthritis patients: comparative efficacy of four treatment regimens
MTX and GC combinations are the most effective for early rheumatoid arthritis.
research Topical treatment with the bacterium-derived c-Met agonist InlB321/15 accelerates healing in the abrasion wound mouse model
Applying InlB321/15 to wounds sped up healing in mice.
research Teriflunomide: a novel oral treatment for relapsing multiple sclerosis
Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.
research 877 Loss of UBE2N in keratinocytes leads to skin inflammation and immune infiltration through IRAK1/4-mediated processes
Removing UBE2N from skin cells causes inflammation and immune response, which can be lessened with specific inhibitors.
research Poster Presentations
Ustekinumab successfully treated a man's resistant skin condition when other treatments failed.
research 52709 Patient-Reported Outcomes for Scalp, Eyebrow and Eyelash Hair Loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 152 Week Results from two Phase 3 Clinical Trials
Baricitinib helps long-term hair regrowth in severe alopecia areata patients.
research Experimental evaluation of ebastine, a second-generation anti-histamine, as a supportive medication for alopecia areata
Ebastine may help regrow hair in alopecia areata patients.
research Rituximab for Bone Lymphoma
Rituximab effectively treated a woman's bone lymphoma that was resistant to other treatments.
research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
research AB0987 ANIFROLUMAB TREATMENT IMPROVES QUALITY OF LIFE AND DECREASES SYSTEMIC CORTICOSTEROID USE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Anifrolumab improves quality of life and reduces steroid use in lupus patients.
research Scattered Skin Eruptions in a Patient With Inflammatory Bowel Disease
A woman with inflammatory bowel disease improved after treatment with ustekinumab for a rare skin condition associated with her disease.
research Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
research 44047 Long Term Real-World Treat-to-Target Skin Clearance and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry
Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.